Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.
Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.
Transcript
What CAR T therapies do you see coming down the pipeline and how do they differ from each other?
That's a loaded question; there's a lot. For the currently approved products, we're learning to use them earlier in lines of care. For the diffuse large B-cell lymphoma population, those indications, and second-line therapy should be coming anytime in the next week to the next couple of months.
Then, we are looking at expanding indications to larger disease states. Obviously, we've had a lot of great approvals with the multiple myeloma products. That recent approval was just on February 28, so I think myeloma is good for a little bit.
In terms of CAR T specifically, for immune effector cells, the bispecifics are the next thing that we're really excited about. We're also looking at allogeneic CAR T products, which are off the shelf, which would really significantly decrease the manufacturing time that we are challenged with at this point.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
Best of Managed Care Cast: Top 5 Episodes From the First Half of 2025
July 18th 2025These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® produced over the first half of 2025. Give them all another listen, and perhaps learn something new.
Read More